You Position: Home > Paper
The comparison of islet β-cell function and insulin resistance between glucose-in-target-level therapy and routine therapy in patients with newly diagnosed type 2 diabetes
( views:396, downloads:149 )
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF DIABETES
- Issue:
- 1
- DOI:
- 10.3969/j.issn.1006-6187.2010.01.002
- Key Word:
- 糖尿病,2型;β细胞功能;胰岛素抵抗
Abstract： 目的 探讨强化治疗与常规治疗对初诊T2DM患者胰岛β细胞功能和胰岛素抵抗(IR)的影响. 方法 初诊T2DM患者选用非胰岛素促泌药物治疗后,HbA_1c≤6.5%者53例,>6.5%者58例,对OGTT血糖、Ins、HOMA-β、HOMA-IR进行组间比较. 结果 与常规组比较,达标组OGTT的5个时点血糖均显著降低(P均<0.01);180min Ins明显降低(P<0.05),其他时点Ins也降低,但无统计学差异(P>0.05);HOMA-IR明显降低,HOMA-β明显升高(P均<0.05);葡萄糖处置指数显著升高(P<0.01);△I_(30)/△G_(30)和AUC_(Ins)组间差异无统计学意义(P>0.05). 结论 初诊T2DM患者早期血糖强化达标治疗比常规治疗更能有效改善高血糖状态,减轻IR程度,提高β细胞基础分泌功能.
- [1]李延兵,翁建平.保护β细胞功能以改善2型糖尿病的自然病程[J].2005,(3).
- [2]蔡明江,张南雁,成杰,等.新诊断2型糖尿病胰岛素强化治疗与常规治疗的对比研究[J].2004,(5).
- [3]叶新华,杜云峰,高剑波,等.短期诺和锐强化治疗对初诊2型糖尿病患者胰岛β细胞功能的影响[J].2005,(2).
- [4]Cano R,Contreras F,Bermudez-Pirela VJ,etc.Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.[J].2007,14(2).